Clinical Trial Update: Ranibizumab Vs Bevacizumab for Type 1 Retinopathy of Prematurity [Phase 3]

View source ↗

Summary

Phase 3 trial comparing ranibizumab vs bevacizumab for retinopathy of prematurity (type 1) in both eyes; current status is UNKNOWN.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinopathy of Prematurity

Drugs mentioned

• Bevacizumab (bevacizumab)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Zagazig University | Conditions: Retinopathy of Prematurity Both Eyes | Phase 3 | Status: UNKNOWN